Antibody-based testing for emtricitabine (FTC), a critical component of pre-exposure prophylaxis and antiretroviral therapy, would provide low-cost detection for clinical monitoring to improve adherence. We developed a mAb (5D2) to FTC and demonstrated its high specificity and physiologically relevant linear range of detection in a competitive enzyme immunoassay. Thus, this mAb is a key reagent that will enable simple and low-cost lateral flow assays and enzyme immunoassays for adherence monitoring.
CITATION STYLE
Youngpairoj, A. S., Vanderford, T. H., Reed, M. S., Granade, T. C., Pau, C. P., Pohl, J., … Heneine, W. (2022). A mAb for the detection of the antiretroviral drug emtricitabine. AIDS, 36(13), 1890–1893. https://doi.org/10.1097/QAD.0000000000003357
Mendeley helps you to discover research relevant for your work.